Company profile
Prime Medicine, Inc.
NASDAQ: PRME · Healthcare · Biotechnology
#713 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
37DFH 30DQ 44GM —SS 52
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ listing tenure, operating margin
Methodology →Revenue TTM
$4.0M
Rev growth YoY (TTM)
+4.9%
Net income (FY)
-$201.1M
Employees
146
as of 2026-08-11
Market cap
$568.9M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.6M$4.6M2025
Net income-$201.1M-$201.1M2025
Operating income-$208.3M-$208.3M2025
Total assets$342.7M$342.7M2025
Liabilities$221.9M$221.9M2025
Equity$120.9M$120.9M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY22
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Prime Medicine, Inc.’s revenue?
Prime Medicine, Inc. booked $4.6M in FY2025 revenue, growing 55% year over year — faster than most Healthcare companies we track, at a -4342.4% net margin.
Peers · Healthcare
InMed Pharmaceuticals Inc.45DPicard Medical, Inc.25DLucid Diagnostics Inc.35DHealthy Extracts Inc.69BOcugen, Inc.44DLift & Co. Corp.——Neighbors
Middlesex →Key facts
CEOAllan Reine
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: PRME
Employees146
IPO date2022-10-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.